Inosine-Mediated Modulation of RNA Sensing by Toll-Like Receptor 7 (TLR7) and TLR8

Soroush T. Sarvestani,* Michelle D. Tate,† Jessica M. Moffat,‡,§ Ashley M. Jacobi,*, Mark A. Behlke,*, Alistair R. Miller,*, Simone A. Beckham,*, Claire E. McCoy,*, Weisan Chen,† Justine D. Minter,† Meredith O’Keeffe,*, Matthias John,*, Bryan R. G. Williams,*, Michael P. Gantier*

Centre for Cancer Research, Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia; Centre for Innate Immunity and Infectious Diseases, Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia; Department of Microbiology and Immunology, The University of Melbourne, Parkville, Victoria, Australia; The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Integrated DNA Technologies Inc., Coralville, Iowa, USA; Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, Victoria, Australia; Centre for Immunology, Burnet Institute, Melbourne, Victoria, Australia; Roche Kulmbach GmbH, Kulmbach, Germany.

RNA-specific adenosine deaminase (ADAR)-mediated adenosine-to-inosine (A-to-I) editing is a critical arm of the antiviral response. However, mechanistic insights into how A-to-I RNA editing affects viral infection are lacking. We posited that inosine incorporation into RNA facilitates sensing of nonself RNA by innate immune sensors and accordingly investigated the impact of inosine-modified RNA on Toll-like receptor 7 and 8 (TLR7/8) sensing. Inosine incorporation into synthetic single-stranded RNA (ssRNA) potentiated tumor necrosis factor alpha (TNF-α) or alpha interferon (IFN-α) production in human peripheral blood mononuclear cells (PBMCs) in a sequence-dependent manner, indicative of TLR7/8 recruitment. The effect of inosine incorporation on TLR7/8 sensing was restricted to immunostimulatory ssRNAs and was not seen with inosine-containing short double-stranded RNAs or with a deoxy-inosine-modified ssRNA. Inosine-mediated increase of self-secondary structure of an ssRNA potentiated tumor necrosis factor alpha (TNF-α)/H9251 and interferon-α/β-deficient cells. There was a correlation between hyperediting of influenza A viral ssRNA and its ability to stimulate TNF-α, independent of 5′-triphosphate residues, and involving Adar-1. Furthermore, A-to-I editing of viral ssRNA directly enhanced mouse Tlr7 sensing, when present in proportions reproducing biologically relevant levels of RNA editing. Thus, we demonstrate for the first time that inosine incorporation into immunostimulatory ssRNA can potentiate TLR7/8 activation. Our results suggest a novel function of A-to-I RNA editing, which is to facilitate TLR7/8 sensing of phagocytosed viral RNA.

Early detection of viral infection is a critical step in the initiation of innate and adaptive antiviral responses, ultimately resulting in viral clearance. This detection relies on the selective sensing of viral components such as viral RNA and involves specific innate immune sensors, including Toll-like receptors (TLRs) and retinoic acid gene induced I (RIG-I)-like receptors. Critically, sensing by these receptors must discriminate between self and nonself RNA to protect the host in homeostatic conditions. This is achieved, for example, through the specific detection of 5′-triphosphate residues present on viral RNAs, which facilitate RIG-I activation (1). In addition, restriction of RNA-detecting TLRs, including TLR3, TLR7, and TLR8 (TLR3/7/8), to the endosomal compartment helps safeguard contact with endogenous RNAs. Nonetheless, such compartmentalization of TLR3/7/8 does not restrict sensing of phagocytosed self-RNAs. Natural modifications of self RNA help to dampen aberrant detection of RNA from phagocytosed cells, as seen with pseudouridine and 2′-O-methyl nucleoside incorporation in RNA—which represents the bulk of cellular RNA—and the 5′ cap of mRNAs inhibiting RNA sensing by TLR7 (2–4) and melanoema differentiation-associated gene 5 (MDA-5) (4).

RNA editing is a posttranscriptional modification of RNA, converting specific adenosine (A) residues into inosine (I) residues (referred to as A-to-I editing). It is critical to development (5), and alteration in editing profiles is associated with several pathologies (6). Recent genome-wide RNA studies indicate that RNA editing is a widespread event, affecting up to 22,000 sites across the human transcriptome (7). A family of enzymes known as RNA-specific adenosine deaminases (ADARs) carry out A-to-I RNA editing. Owing to their specific interaction with double-stranded RNA (dsRNA) regions, editing of RNA by ADARs is limited to RNA regions with high secondary structure (at least 15 to 20 bp long [8]), such as Alu-containing sequences (7).

ADAR-1, one of the two active mammalian deaminases, possesses a type I interferon (IFN)-inducible variant (ADAR-1L or p150), which is induced following detection of viral infection (9). ADAR-1L is an established component of the antiviral response to certain viral infections, and viral products have evolved to block its activity (9). By virtue of its ability to associate with adenosine, cytidine, and uridine through non-Watson-Crick wobble base
pairing, inosine incorporation into double-stranded regions of viral RNA directly affects the encoded protein sequences (10). ADAR-1L-deficient mouse embryonic fibroblasts display heightened replication of paramyxoviruses (such as measles virus) and orthomyxoviruses (such as influenza A virus), providing direct evidence of the antiviral activity of RNA editing through ADAR-1L for these viruses (5). However, there is no clear understanding of how A-to-I editing exerts its antiviral effect on such viruses. Reports suggest that inosine-rich single-stranded RNAs (ssRNAs) can potentiate TLR3 sensing (11, 12), through the modulation of RNA secondary structures (11). These findings indicate that in addition to its direct effect on viral coding sequences, A-to-I editing could be used by the cell to facilitate innate immune recognition of foreign RNA.

Endosomal TLR7/8 are specialized in the detection of foreign ssRNAs (13) and are critical to the mounting of an effective innate and adaptive immune response against several viruses (14–16). TLR7 and TLR8 recognize different RNA sequences on the basis of specific motifs (17). In humans, TLR7 is predominantly expressed in plasmacytoid dendritic cells (pDCs), which is related to its ability to induce high levels of IFN-α (13); TLR8, on the other hand, is restricted mostly to monocytes/macrophages, explaining its ability to drive high tumor necrosis factor alpha (TNF-α) production (13). Conversely, mouse Tlr7 is expressed in both pDCs and monocytes and is essential to RNA sensing, while mouse Tlr8 is dispensable (13). As such, it is well accepted that IFN-α production is indicative of TLR7 recruitment and that production of TNF-α reflects TLR8 engagement following ssRNA transfection in human peripheral blood mononuclear cells (PBMCs) (13). In mice, however, both TNF-α and IFN-α production relate to Tlr7 activation (13). We and others have previously established that TLR7/8 sensing of ssRNAs is strongly dependent on the propensity of ssRNAs to form inter- and intramolecular secondary structures, with the limitation that perfect dsRNA molecules are less stimulatory than imperfect ones (13, 18, 19). Whether or not inosine incorporation in RNA can modulate TLR7/8 sensing has not been characterized to date.

Here, we investigate the impact of inosine incorporation into ssRNAs on the activation of TLR7/8. We establish that inosine incorporation in ssRNA can increase TLR7/8 sensing, in a sequence-specific manner. Our findings provide evidence that A-to-I editing of structured viral RNAs can act to facilitate their sensing by TLR7/8.

**MATERIALS AND METHODS**

**Cell isolation and culture.** Blood was collected from healthy male donors in heparin-treated tubes. PBMCs were purified with Ficoll-Paque plus (GE Healthcare) as previously reported (20). PBMCs were plated at 200,000 per well of a 96-well plate in 150 μl of RPMI 1640 plus l-glutamine (Invitrogen Corporation), supplemented with 1% anti-biotic/antimycotic and 10% fetal bovine serum (FBS) (Invitrogen Corporation), referred to as complete RPMI. The cells were incubated for 4 h at 37°C in 5% CO2 atmosphere before stimulation by ssRNAs and dsRNAs. Immortalized Tbr7−/− bone marrow macrophages (BMMs) and wild-type (wt) BMMs were generated using the J2 retrovirus encoding v-raf and v-myc as previously described (19) and were maintained in 80% Dulbecco’s modified Eagle medium (DMEM) supplemented with 1% anti-biotic/antimycotic and 10% FBS (referred to as complete DMEM), with 20% L-929 cell-conditioned medium. Human acute monocytic leukemia (THP-1) cells were grown in suspension in complete RPMI. Mouse LA-4 lung epithelial cells were grown in F-12K nutrient mixture, Kaighn’s modification (Gibco). THP-1, Tbr7−/−, and Tbr7wt/wt BMMs were passaged 1:3 or 1:5 every 2 or 3 days, respectively. For THP-1 experiments, 80,000 phorbol myristate acetate (PMA)-activated cells were primed for 6 h with 100 U/ml IFN-γ (10 U/ml; Chemicon) before stimulation with ssRNAs, as previously described (21, 22).

**Isolation of BMMs.** For stimulation of primary mouse BMMs with ssRNAs, bone marrow extraction and differentiation were carried out following standard procedures (23). Briefly, femurs from wild-type C57BL/6 mice were flushed with complete DMEM, and cells were plated in complete DMEM supplemented with 20% L-929 cell-conditioned medium in T75-treated flasks for 6 days at 37°C in a 5% CO2 atmosphere. On day 6, the cells were collected, plated at 80,000 cells per well of a 96-well plate in 150 μl DMEM complete, and incubated overnight at 37°C in 5% CO2 atmosphere prior to stimulation on day 7.

**Isolation of murine plasmacytoid dendritic cells.** Splenic DCs were isolated from age-matched wild-type and Tbr7-deficient (24) spleens, as previously reported (25). pDCs were further sorted from splenic DCs by flow cytometry, based on the expression of CD11c and CD45RA ‘Ly6c’ (26).

**Synthetic RNAs for stimulation of cells.** ssRNAs, dsRNAs, and small interfering RNAs (siRNAs) were synthesized as ssRNAs by Integrated DNA Technologies (IDT) with high-pressure liquid chromatography (HPLC) purification and resuspended in duplex buffer (100 mM potassium acetate, 30 mM HEPES [pH 7.5], DNsase/Rnase-free H2O) to 80 μM. Annealing of dsRNAs (see Fig. 2) was performed as previously reported (20, 22). ss/dsRNAs and purified viral RNAs were transfected with diethyltriaminopentamethylene propane (DOTAP; Roche) and pure RPMI in biological triplicate as previously described (19–22). The ratios of DOTAP to ssRNA (at 80 μM) were 3.74 μg/μl of ssRNA (see Fig. 1, 2, 3, and 6D) and 7.78 μg/μl of ssRNA (see Fig. 6B and C). Following stimulation, the samples were incubated overnight for 16 to 18 h before cytokine measurement by enzyme-linked immunosorbent assay (ELISA). Gardiquimod (chemical TLR7 agonist), Pam3CSK4 (TLR2/1 agonist), CL075 (mouse TLR7 and human TLR8 chemical agonist), and R848 (human TLR7/8 chemical agonist) were used as positive controls. Sequences of nonimmunostimulatory ss41 RNA (ss41-N) and 2’-O-methyl (2’Ome) RNA (AMO NC) were previously reported (19, 27). A DOTAP-only (referred to as ‘Mock’) control was used in all experiments to control for the effect of DOTAP. The control ligands were purchased from Invivogen and were directly added to medium to a final concentration of 1 to 2 μg/ml (Gardiquimod, CL075, and R848) or 100 ng/ml (Pam3CSK4). Stimulation was carried out in biological triplicate in all experiments.

**Detection of cytokines.** Human TNF-α and mouse TNF-α were measured using BD Opteia ELISA sets according to the manufacturer’s instructions (BD Biosciences). Human and mouse IFN-α detection was carried out by sandwich ELISA as previously reported (21, 22, 26). Tetramethylbenzidine substrate (Sigma-Aldrich) was used for quantification of the cytokines on a Fluostar Optima (BMG Labtech) plate reader.

**SYBR green melt curve assay.** The SYBR green melt curve assay relies on the ability of SYBR green to fluoresce up to 1,000-fold more intensely when intercalated in the minor groove of two strands of nucleic acids and is adapted from studies of DNA melt curves (28). Approximately 2 μg of ssRNA (4 μl of 80 μM ssRNA) diluted in 10 μl duplex buffer was mixed with 10 μl of Power SYBR green PCR Master Mix (Applied Biosystems) and analyzed on a Bio-Rad q5 iCycler. Following denaturation of ssRNAs for 4 min at 95°C, the samples were cooled to 20°C using a minimal ramp (to allow formation of secondary structures) and kept for 1 min at 20°C prior to being subjected to the melting curve (from 20°C to 95°C—151 steps of 0.5°C increments, 10 s per step). For each melt curve, relative fluorescence units (RFU) measured were corrected for background RFU at 95°C and reported to the fluorescence measured at 20°C.

**Isolation of influenza virus RNA.** Type A influenza virus strains A/PB/8/34 (H1N1) (PR8) and A/Brazil/11/78 (H1N1) (BRA) were grown in 10-day-old embryonated hen’s eggs using standard procedures (29). Cells from allantoic fluid were pelleted at 14,000 rpm for 30 min at 4°C,
and the RNA was extracted from the cell pellet using the RNasy Minikit (Qiagen) according to the manufacturer’s instructions. RNA concentrations were quantified using a Nanodrop (Thermo Scientific). For RNA from infected cells, a T-75 flask of LA-4 cells was infected with strain PR8 or with a PR8 virus lacking the NS1 gene (referred to as PR8-NS1 or PR8-NS1-ΔNS1; a kind gift from A. Garcia-Sastre [30]) for 24 h (multiplicity of infection 0.1) and the RNA was extracted from the cell pellet using the RNeasy Minikit (Qiagen) diluted in 750 μl of馏水 (water). The sequences of Adar-1 and NC5 D-siRNAs are given in Table 1.

Table 1. DNA oligonucleotides used in the study

<table>
<thead>
<tr>
<th>Name of DNA sequence</th>
<th>Sequence*(5’–3’)</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>FWD-PR8-norm</td>
<td>AGGGGTGTTTGACACTTCGT</td>
<td>RT-qPCR of native genomic sequence: 100-bp amplicon (positions 829–928 of GenBank sequence EF47821.1)</td>
</tr>
<tr>
<td>REV-PR8-norm</td>
<td>CACCAAGTATGTTTTGCCACT</td>
<td>RT-qPCR of hyperedited genomic variant</td>
</tr>
<tr>
<td>FWD-PR8-edited</td>
<td>AGGGGTGTTTGCGCTTTGCT</td>
<td>RT-qPCR of native genomic sequence: 104-bp amplicon (positions 815–918 of GenBank sequence CY020931.1)</td>
</tr>
<tr>
<td>REV-PR8-edited</td>
<td>CAACCAAGCTATGTTTTGCCACT</td>
<td>RT-qPCR of hyperedited genomic variant</td>
</tr>
<tr>
<td>FWD-BRA-norm</td>
<td>TGTTGTTTGACACTTCGT</td>
<td>RT-qPCR of native genomic sequence: 100-bp amplicon (positions 829–928 of GenBank sequence EF47821.1)</td>
</tr>
<tr>
<td>REV-BRA-norm</td>
<td>ATAGCCATGATGTGTTTTT</td>
<td>RT-qPCR of hyperedited genomic variant</td>
</tr>
<tr>
<td>FWD-BRA-edited</td>
<td>TGTTGTTTGCGCTTTGCT</td>
<td>RT-qPCR of hyperedited genomic variant</td>
</tr>
<tr>
<td>REV-BRA-edited</td>
<td>ATAGCCATGACAGTGTGTTTTT</td>
<td>RT-qPCR of hyperedited genomic variant</td>
</tr>
<tr>
<td>DS-BRA-FWD</td>
<td>CCATCTCATCCCCGTTGTGCTTCCCTGCGT</td>
<td>Mouse Adar-1 siRNA</td>
</tr>
<tr>
<td>DS-BRA-REV</td>
<td>CCATCTCATCCCCGTTGTGCTTCCCGCGT</td>
<td>Mouse Gapdh RT-qPCR</td>
</tr>
<tr>
<td>mAdar-3442S3</td>
<td>CCATCTCATCCCCGTTGTGCTTCCCGCGT</td>
<td>Mouse Adar-1 RT-qPCR</td>
</tr>
<tr>
<td>mAdar-3442AS12</td>
<td>CCATCTCATCCCCGTTGTGCTTCCCGCGT</td>
<td>Nontargeting control siRNA</td>
</tr>
<tr>
<td>NC5 S3</td>
<td>CCATCTCATCCCCGTTGTGCTTCCCGCGT</td>
<td>Nontargeting control siRNA</td>
</tr>
<tr>
<td>NC5 AS12</td>
<td>CCATCTCATCCCCGTTGTGCTTCCCGCGT</td>
<td>Nontargeting control siRNA</td>
</tr>
<tr>
<td>mAdar-FWD</td>
<td>GGCGGAGTCAGGTTTAGTGTGAT</td>
<td>Mouse Gapdh RT-qPCR</td>
</tr>
<tr>
<td>mAdar-REV</td>
<td>GAACACTCTTCCCTTCCGCGT</td>
<td>Mouse Gapdh RT-qPCR</td>
</tr>
<tr>
<td>mGAPDH-FWD</td>
<td>TTACCAACATGGAAAGGCC</td>
<td>Mouse Gapdh RT-qPCR</td>
</tr>
<tr>
<td>mGAPDH-REV</td>
<td>GGCGGAGTCAGGTTTAGTGTGAT</td>
<td>Mouse Gapdh RT-qPCR</td>
</tr>
</tbody>
</table>

*Uppercase, DNA base; A-to-G and T-to-C mutations are in lowercase; the sequence-specific regions are in italics; m, 2′OMe modification; r, RNA base.

Ion Torrent sequencing primers; sequencing is from the reverse primer (gives antigenomic sequence).

**RT-qPCR.** Viral RNA (50 ng) was reverse transcribed into cDNA using the High-Capacity cDNA archive kit (Applied Biosystems) according to the manufacturer’s instructions. Reverse transcription quantitative real-time PCR (RT-qPCR) was carried out with the SYBR Green ER qPCR SuperMix for iCycler instrument (Invitrogen Corporation) on a Bio-Rad iQ5 iCycler. Amplification of viral genomes was carried out using specific primers for a normal and hyperedited 100-bp region of both PR8 and BRA strains (within the HA gene). These regions were inferred from previous reports of influenza virus hyperedited sequences (31). Amplicons were sequence verified and used to generate standard curves for the quantification of gene expression. Relative editing was calculated by normalizing hyperedited RNA levels to normal RNA levels. The sequences of the primer pairs used are described in Table 1.

**Ion Torrent sequencing using the fusion PCR method.** Cycle- limited PCR using specific Ion Torrent compatible primers (see DS primer in Table 1) was carried out on the viral cDNA previously used for RT-qPCR, using Platinum PCR SuperMix High Fidelity (Applied Biosystems) according to the manufacturer’s instructions. The primers included degenerated bases to allow for equal amplification of edited targets. Hyperedited amplicons were purified by gel migration and Agencourt AMPure XP Reagent (Applied Biosystems), before normalization and pooling (BRA and PR8 samples were pooled). RNA sequencing was carried out using one 318 Ion Torrent chip with 200-bp chemistry according to the manufacturer’s protocol. RNA sequencing was carried out in reverse orientation to the genomic viral RNA. We obtained a total of 1,029,246 reads and 1,202,254 reads for the PR8 and BRA samples, respectively.

**Bioinformatic analysis of Ion Torrent sequencing.** Sequences were aligned to reference viral sequences CY020931.1 and EF47821.1 (GenBank) using Torrent Suite 2.2 software (Life Technologies). Identification of the number of mutations (A-to-G, C-to-U, etc.) for each read was computed using a proprietary Perl script that utilized the Bio::DB::Sampler module (available from http://search.cpan.org/~lds/Bio-SamTools/lib/Bio/DB/Sam.pm). Critically, we noticed that inclusion of primer sequences strongly biased the occurrences of A-to-G mutations relative to genomic viral RNA, and we therefore excluded primer regions in our analyses.

**Adar-1 RNA interference of LA-4 cells by reverse transfection.** A highly potent siRNA targeting the three main three-splice variants of mouse Adar-1 (NM_001038587, NM_001146296, and NM_019655) was selected through high-throughput screening of 24 siRNA duplexes (IPT). A 0.75-μl volume of mouse Adar-1 Dicer-substrate siRNA (D-siRNA) or a targeting noncontrol (NC5) D-siRNA resuspended in duplex buffer to 250 μM was mixed to 750 μl of Opti-MEM (Invitrogen Corporation), prior to being added to 50 μl of Lipofectamine RNAiMax (Invitrogen Corporation) diluted in 750 μl Opti-MEM for 10 min. One T-75 flask of LA-4 cells was split to seed two T-75 flasks in 1 ml complete medium. The D-siRNA-RNAiMax mix was added to each flask, resulting in a final volume of 16.5 ml, with ~11 nM siRNA. The cells were incubated for 16 h prior to rinsing and infection with PR8-ΔNS1 for another 24 h and RNA extraction. The sequences of Adar-1 and NC5 D-siRNAs are given in Table 1.

January 2014 Volume 88 Number 2 jvi.asm.org 801

Downloaded from http://jvi.asm.org on November 6, 2017 by guest
RESULTS

Inosine incorporation in ssRNA can potentiate RNA sensing by immune cells. We and others have previously reported that although directly dependent on the presence and proportion of uridine residues and associated motifs, TLR7/8 sensing of ssRNAs could be modulated by the propensity of RNAs to form inter- and intramolecular secondary structures (18, 19, 22, 32). To investigate the potential effect of inosine incorporation into ssRNAs on innate immune sensing, we initially studied the immunostimulatory profiles of a set of 25-nucleotide (nt) synthetic RNAs. These included five inosines dispersed throughout the center of the oligonucleotide (ssIA), a central stretch of four consecutive inosines (ssIB), and a central stretch of four consecutive uridines (ssU) (Fig. 1A). The human TLR8-specific chemical agonist CL075 (also known as 3M002) was used as a positive control. Human PBMCs stimulated with increasing concentrations of liposome-complexed ssRNAs showed a strong increase in TNF-α production with ssIA and ssU, while an increase was seen only at 600 nM with ssIB, compared to the native ssN sequence (Fig. 1B). However, IFN-α levels were not increased with ssIA or ssIB (Fig. 1B), suggesting that the inosine modification of ssIA primarily affected TLR8 sensing (13). In addition, the ability of ssIA to induce greater immunostimulation than ssN was also observed in TLR8-responsive human monocytic THP-1 cells (22) (Fig. 1C) but was absent in mouse BMMs, which lack the Tlr8 response (22) (Fig. 1D). CL075, which activates Tlr7 in mouse, was used as a positive control. Collectively, these results suggest that selective inosine incorporation into ssRNAs could potentiate sensing by TLR8 in the context of this ssRNA sequence.

The effect of inosine incorporation on TLR7/8 sensing is restricted to immunostimulatory ssRNAs. Our observation that ssIA exerted increased TLR8 recruitment compared to ssIB indicated that the position of inosine residues within the ssRNA sequence was critical in their effect on TLR8 sensing and that potentiation of immune stimulation did not relate to the presence of the inosine residues alone. To confirm this hypothesis, we investigated the impact on cytokine production of five inosines dispersed throughout the center of an oligonucleotide devoid of uridine residues (ss41-L), which does not activate TLR7/8 (19, 33) (Fig. 2A). ss41-L and its inosine variant, ss41-L-I, failed to significantly induce any TNF-α (Fig. 2B) or IFN-α (data not shown) production in human PBMCs, even at high dose. On the other hand, mFOLD structural in silico prediction of ssN used in the experiment illustrated in Fig. 1 indicated that this oligonucleotide was prone to a high degree of self secondary structure (Fig. 2C, right). Inosine and its DNA variant, deoxy-inosine, can form wobble base pairing with adenosine, cytidine, and uridine. We therefore speculated that some of the effects of inosine incorporation in ssIA and ssIB could be due to modifications of secondary structures. To assess this hypothesis, we next studied TLR7/8 recruitment by ssN, ssIA, ssIB, and ssU duplexed to the complementary sequence of ssN (resulting in dsN, dsIA, dsIB, and dsU) (Fig. 2C, left). Experiments in human PBMCs showed no increase in TNF-α or IFN-α production with either dsIA or dsIB compared to ssN (Fig. 2D), directly implicating formation of secondary structures in the effect of inosine incorporation in ssIA and ssIB. To determine whether structural variations, independent of inosine residues, were responsible for increased immune stimulation, we studied the immunostimulatory activity of a variant of ssIA synthesized with DNA deoxy-inosine residues substituted for inosine residues (ssdIA). Unlike ssIA, ssdIA failed to increase TNF-α/IFN-α pro-

Statistical analyses. Statistical analyses were carried out using Prism 5 (GraphPad Software Inc.). Two-tailed unpaired t tests with Welch’s correction were used from a minimum of six biological values (from a minimum of two independent experiments). Significance was noted as follows: * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; ns, nonsignificant.

FIG 1 Inosine incorporation into ssRNA can increase cytokine production by human immune cells. (A) Sequence details of the synthetic small RNAs used. Ribo-inosine and uridine variations from the native sequence ssN are highlighted in bold. (B) The indicated ssRNAs were transfected with DOTAP at the indicated doses in human PBMCs and incubated overnight. Cytokine production was measured by specific ELISA. Data shown are averaged from two independent experiments in three blood donors, in biological triplicate. Unpaired t tests comparing the ssRNA to ssN, for the same concentration, are shown. (C) Human THP-1 cells were activated with PMA overnight and primed for 6 h with IFN-γ prior to rinsing and stimulation with 600 nM the indicated ssRNAs complexed with DOTAP. Following a further 16 h of incubation, the supernatants were collected and assayed for TLR7-α levels. Data shown are averaged from three independent experiments in biological triplicate. Unpaired t tests are shown in panels C and D. ssU (B) and CL075 (C and D) were used as positive controls for TLR7-α levels. Standard errors of the means (SEM) are shown in panels B to D.
Inosine Modulation of TLR7/8 Sensing

FIG 2  Inosine content of ssRNA does not have a direct positive impact on TLR7/8 sensing. (A) Sequence details of the synthetic small RNAs used. Riboi-nosines are shown in bold. (B) The indicated ssRNAs were transfected with DOTAP to a final concentration of 600 nM in human PBMCs. Cytokine production was measured by specific ELISA following overnight incubation. Data shown are averaged from five independent experiments, in biological triplicate. Unpaired t tests comparing the dsRNA to dsN are shown. SEM is shown in panels B, D, and E.

duction in human PBMCs (Fig. 2E), underlining the critical role for ribo-inosine moieties in the effect of ssIA. Collectively, these results suggested that unlike uridine residues, ribo-inosine residues did not directly activate TLR7/8 but rather potentiated sensing of uridine motifs through modulation of inter- and intramolecular secondary structures.

Inosine-mediated structural modification of ssRNA modulates TLR7 sensing. In order to further ascertain the ability of inosine incorporation to modulate TLR7/8 sensing through the modulation of ssRNA structure, we investigated the effect of a single inosine mutation on the secondary structure and immune activity of a previously characterized immunostimulatory ssRNA (19). Relying on the correlation between mFOLD-predicted (34) secondary structures of ssRNAs and the fluorescence of ssRNAs with the nucleic acid intercalating SYBR green (data not shown), we first demonstrated that inosine incorporation into B-406-AS (giving B-406-AS-i), resulting in the formation of an I·C base pair, robustly increased the strength of the intramolecular secondary structure of this ssRNA, as revealed by the higher energy (temperature) required to decrease SYBR green fluorescence by 80% (Fig. 3A and B, compare B-406-AS and B-406-AS-i). Importantly, the wobble I·C pair in B-406-AS-i was less potent than the G·C pair in B-406-AS-1 in its ability to modulate intramolecular secondary structure, as revealed by the SYBR green melt curve assay (Fig. 3A and B, compare B-406-AS-i and B-406-AS-1). In agreement with a role for secondary structure in the modulation of TLR7/8 signaling (19), the I·C base pair of B-406-AS-i robustly increased the immobilistic activity of this ssRNA in human PBMCs compared to the native B-406-AS sequence, but not as potently as the G·C pair of B-406-AS-1, which conferred greater secondary structure (Fig. 3C, compare B-406-AS, B-406-AS-i and B-406-AS-1). Importantly, in the context of the B-406-AS ssRNA, inosine modification potentiated IFN-α rather than TNF-α production, suggesting a preferential effect of inosine on TLR7 (22). To determine the direct involvement of TLR7 in the effect of B-406-AS-i, we assessed the ability of B-406-AS-i to induce immune stimulation when cotransfected with an RNA containing 2’O-methyl (2’Ome) groups, given that 2’Ome-modified RNAs act as TLR7 antagonists (Fig. 3D) (3). 2’Ome RNA cotransfection entirely ablated B-406-AS-i-induced IFN-α production, consistent with the requirement of TLR7 in the sensing of the inosine modification. Nonetheless, 2’Ome RNA cotransfection did not ablate TNF-α production by B-406-AS-i, suggesting residual TLR8 sensing, nor did it prevent IFN-α production by the TLR9 ligand CpG DNA (Fig. 3D). Similarly, the requirement for TLR7 in the sensing of B-406-AS-i was confirmed using pDCs from Tlr7−/− mice, which lacked IFN-α production in response to B-406-AS-i but not the Tlr9 agonist (Fig. 3E). Taken together, these results demonstrate that selective inosine incorporation into ssRNA can potentiate TLR7 RNA sensing, through its impact on inter- and intramolecular secondary structures.

Increased inosine content in viral RNA correlates with increased TNF-α production in human PBMCs. The data thus far suggested that inosine incorporation into structured short immunostimulatory ssRNA had the potential of increasing TLR7/8 sensing, depending on the sequence modified or the localization of inosine modification(s). To determine the biological significance of these results, we next investigated the impact of inosine incorporation into influenza virus A (ssRNA virus) RNA on its immunostimulatory activity. Relying on RT-qPCR amplification
B-406-AS [ΔG = -0.5]

B-406-AS-1 [ΔG = -3.9]

B-406-AS-i [ΔG = 7]

FIG 3  Inosine modulates TLR7 activity. (A) mFOLD-predicted structure of the B-406-AS series of immunostimulatory ssRNAs (19). C-to-G and C-to-I mutations of B-406-AS resulting in B-406-AS-1 and B-406-AS-i, respectively, are circled. The mFOLD-predicted free energy (ΔG, in kcal/mol), indicative of the strength of the secondary structure of the ssRNAs, is given. (B) Fluorescence-based determination of ssRNA secondary structure, using the SYBR green melt curve assay (see Materials and Methods). An arrow highlights the temperature at which the fluorescence of B-406-AS-i is decreased by 80%. The data are averaged from three independent experiments. (C) The indicated ssRNAs were transfected with DOTAP to a final concentration of 200 nM in human PBMCs and incubated overnight. Cytokine production was measured by specific ELISA. Data shown are averaged from two independent experiments in two blood donors, in biological triplicate. (E) Splenic pDCs from Tlr7−/− mice and Tlr7−/− mice were stimulated with 100 nM DOTAP-complexed B-406-AS-i ssRNA or 5 μM CpG DNA and incubated overnight. Mouse IFN-α production was measured by specific ELISA in technical triplicate. The data are averaged from two independent experiments. SEM is shown in panels B to E.
aberrant activation of innate immune sensors from self-RNA (2). In line with this concept and the direct inhibitory effect of 2′-O-methyl moieties in Tlr7 sensing (3), total RNA from epithelial cells transfected in human PBMCs did not induce production of IFN-α or TNF-α (Fig. 5A, condition “Cells only”). Conversely, total RNA from influenza virus PR8-infected epithelial cells, containing more than 60% of 18S and 28S rRNA (data not shown), induced a strong IFN-α production concurrently with a mild TNF-α secretion in human PBMCs (Fig. 5A, PR8 and PR8-ΔNS1 conditions). Calf intestinal phosphatase (CIP) treatment of the RNA from PR8-infected cells resulted in a strong reduction in IFN-α production (compare IFN-α levels in Fig. 5A and B), indicating the involvement of 5′-triphasphate moieties in IFN-α production (1). Nonetheless, RNA from cells infected with a mutant PR8 virus lacking the NS1 protein (which is thought to impair ADAR-1 editing activity [31]) (ΔNS1) retained the ability to induce TNF-α production following CIP treatment, suggestive of TLR8 recruitment rather than RIG-1 activation (35). The RNA from PR8-ΔNS1-infected cells contained a higher proportion of hyperedited PR8 transcripts than RNA from wild-type PR8-infected cells (Fig. 5C), suggesting a putative involvement of RNA editing in this effect. In addition, CIP-treated RNA from PR8-ΔNS1-infected cells retained the ability to activate TNF-α production in immortalized BMMs from Tlr7−/− but not from Tlr7+/− mice (Fig. 5D, compare “PR8-ΔNS1 + CIP” conditions in Tlr7−/− and Tlr7+/− cells); on the other hand, non-CIP-treated RNA was able to induce TNF-α production independently of the presence of Tlr7, which is indicative of RIG-I recruitment. The Tlr2/1 ligand, Pam3CSK4, confirmed that both Tlr7+/− and Tlr7−/− cells were able to produce TNF-α. To directly involve Adar-1 editing in the TNF-α production seen in RNA from PR8-ΔNS1-infected cells, we decreased Adar-1 expression through RNA interference in LA-4 cells prior to the infection with PR8-ΔNS1 (Fig. 5E, compare siADAR and the control siNC5 conditions). In accord with the results above, CIP treatment of the RNA from PR8-ΔNS1-infected cells showed a significant decrease in IFN-α production in human PBMCs, regardless of Adar-1 expression (Fig. 5F). TNF-α levels, however, were significantly decreased following downregulation of Adar-1 (siADAR condition), but not with the nontargeting control siNC5. This directly implicates Adar-1 in the ability of CIP-treated RNA to induce TNF-α. Collectively, these results suggest that a small proportion of Adar-1-edited viral RNA is able to potentiate sensing of cellular RNA, independently of 5′-triphasphate/RIG-I recruitment, in a human TLR8- and mouse Tlr7-dependent manner.

FIG 4 Hyperediting of viral RNA correlates with increased TNF-α levels in human PBMCs. (A and B) PR8 (A) and BRA (B) viral RNA (−0.4 μg/ml) from two independent eggs was transfected in human PBMCs, and cytokine production was measured after 16 h of incubation (right panels). Data shown are representative of one (BRA) or three (PR8) independent experiments in biological triplicate. The same viral RNA was reverse transcribed and analyzed by qPCR for hyperediting frequency (left panels) (see Materials and Methods). RT-qPCR data shown are averaged from two independent experiments. (C and D) Ion Torrent analysis of PR8 and BRA samples. (C) The number of reads with at least two or more of the same mutation relative to genomic viral RNA is shown for each virus. Total mutations for each strand were combined (e.g., A-to-G and C-to-U mutations were added) to reflect editing of total viral RNA (genomic and antigenic). (D) The number of reads with an increasing amount of A-to-G mutations relative to genomic viral RNA (e.g., >1 means at least one A-to-G mutation) is shown for each virus. (C and D) Mutation analyses of the reads excluded primer regions to avoid sequence bias from degenerated primers (see Materials and Methods). Frequencies of mutations are shown as percentages, relative to the total numbers of reads for each virus (1,029,246 for PR8 and 1,202,254 for BRA). SEM is shown in panels A and B.
A-to-I editing in a proportion of viral RNA potentiates TLR7 sensing. Having shown that (i) purified viral RNA with greater inosine content (Fig. 4) and (ii) RNA from infected cells with greater viral hyperediting (Fig. 5) were more immunostimulatory, we next sought to validate the direct contribution of A-to-I editing on synthetic RNAs encompassing a 90-nt hyperedited portion of PR8 RNA previously analyzed by sequencing (Fig. 6A) (reference 31 and data not shown). We wished to exclude possible self RNA cleavage products that could have contaminated our viral RNA preparations (36). Unexpectedly, comparison of the immunostimulatory profiles of each individual 30-nt segment with (S1i, S2i, and S3i) or without (S1, S2, and S3) inosine editing showed no increase in cytokine production with inosine editing for any of the fragments (Fig. 6B). Noteworthy, there appeared to be a degree of correlation between the frequency of TLR8-specific AU motifs (Fig. 6A, shaded in gray) (17) that were converted to IU motifs and the negative impact of A-to-I editing on TNF-α production. As such, S2i, which lost three AU motifs, displayed a near-significant (P = 0.0512) decrease in the induction of TNF-α compared to S2 (Fig. 6B). Nonetheless, we speculated that formation of complex intermolecular secondary structures could be at play in the effect of inosine on TLR7/8 sensing of viral RNA seen in Fig. 4 and 5, and therefore we studied pools of 30-nt ssRNAs with or without inosine editing (Fig. 6C). While no increase in cytokine production was seen using pure pools of inosine-modified RNA (condition “pool”), the addition of a small quantity of inosine-modified RNAs (12.5%) to the pool of native RNAs resulted in an ~2-fold increase in TNF-α production and a small increase in IFN-α levels in human PBMCs (Fig. 6C, compare “pool” 12.5% with “wtpool” conditions). Significant potentiation of cytokine production with as low as 1% of edited transcripts was confirmed in immortalized BMMs from Tlr7+/+ mice, but not from Tlr7−/− mice, for TNF-α.
First, we observed that inosine addition to short synthetic immune-competent RNA on the potentiation of TLR7 sensing. We provide several lines of evidence supporting the direct effect of inosine incorporation into ssRNAs on TLR7/8 sensing. We performed several experiments in biological triplicate in two blood donors (C) and averaged from three independent experiments in biological triplicate (D). (D) Unpaired two-tailed t tests using "wtpool" as a reference are shown. SEM is shown in panels B, C, and D.

(Fig. 6D) and interleukin-6 (IL-6) production (data not shown). These results establish that small proportions of A-to-I hyperedited RNAs can facilitate sensing of viral RNA by Tlr7.

DISCUSSION

ADAR-1L-mediated A-to-I editing is a critical component of the antiviral response against several viruses, including measles and influenza A viruses (5). A recent report analyzing the A-to-I editing content of influenza A viral RNA from infected chicken fibroblasts suggested that A-to-I editing is frequent during viral replication, potentially modifying up to 1% of viral RNA (31). In our analyses of two strains of influenza A virus, we show that as much as 0.8% of viral RNA can be edited following standard propagation of virus in hens’ eggs (as carried out for the production of influenza vaccine). In accord with the work of Suspene et al., this suggests that A-to-I editing is indeed a frequent event during viral replication (31). We also confirm that both genomic and the replication template of influenza A virus can be edited (31). We found that an important proportion of RNAs with at least three A-to-G mutations had in fact at least six A-to-G mutations, indicative of their hyperediting. However, our observations suggest that hyperedited viral RNAs represent only a fraction of all A-to-I edited RNAs. While such mutations would directly impact the affected clones and their ability to produce effective viruses, it is however most likely that such direct effects on <1% of the clones do not account for much of the overall antiviral properties of ADAR-1L-mediated A-to-I editing. Rather, inosine incorporation in structured viral RNAs could facilitate recognition of nonself RNA (11, 14, 31). Under this rationale, a small proportion of edited viral RNA could elicit a strong antiviral effect through the downstream induction/amplification of type I IFN signaling. This is supported by two independent reports directly implicating a role for inosine residues in the activation of TLR3 (11, 12).

In the current study, we set out to investigate the impact of inosine incorporation into ssRNAs on TLR7/8 sensing. We provide several lines of evidence supporting the direct effect of inosine incorporation into ssRNA on the potentiation of TLR7/8 sensing. First, we observed that inosine addition to short synthetic immu-
nostimulatory ssRNA molecules could result in increased production of IFN-α or TNF-α by human PBMCs, in a sequence-specific manner (Fig. 1, 2, and 3). Given that TLR7 and TLR8 recognize different RNA motifs (17), the sequence-specific potentiation of IFN-α or TNF-α by inosines is indicative of the specific recruitment of TLR7/8. Critically, ablation of IFN-α production of B-406-AS-i with a TLR7 antagonist in human PBMCs, together with the lack of an effect of B-406-AS-i in mouse Tlr7−/− pDCs, directly implicates TLR7 in the detection of inosine-modified ssRNA (Fig. 3). In addition, the finding that the inosine-rich ssIA promoted specific induction of TNF-α in both human PBMCs and PMA-activated THP-1 monocytic cells but not in primary mouse BMMs supports the notion that RNA sensing by human TLR8 can also be facilitated by inosine incorporation (Fig. 1). This is in accord with the observation that the double-stranded form of ssIA, dsIA, did not elicit an increase in TNF-α production, given that TLR8 sensing is strongly repressed by annealing of complementary oligonucleotides (18).

Second, we demonstrate that a nonimmunostimulatory inosine-rich ssRNA, ssA1−L−I (lacking uridine residues), cannot elicit an immune response following DOTAP-mediated delivery in human PBMCs. We and others have previously demonstrated that TLR7/8 sensing is strongly reliant on the presence of uridine residues (19,37), further implicating TLR7/8 in the detection of inosine-modified ssRNA (Fig. 2). Third, it has previously been speculated that TLR7/8 sensing of ssRNAs relates to their tendency to form inter- and intramolecular uridine-rich secondary structures (37). In agreement with this, we have previously observed that the position of uridine modifications within the secondary structure of an ssRNA has an important effect on immunostimulation (22). Given the ability of inosine to form wobble base pairing with adenosine, cytidine, and uridine, inosine incorporation is expected to directly impact on the ability of an ssRNA to form secondary structures. In accord with a role for inosine in the modulation of TLR7/8 sensing through structural variations, we demonstrate here that the position of inosine incorporation is critical to the effect on TLR7/8 sensing (Fig. 1). In addition, we establish a direct correlation between the inosine-mediated modulation of inter- and intramolecular ssRNA structures and activation of TLR7 with B-406-AS-i (Fig. 3). Nonetheless, the effect of inosine on immune stimulation is not limited to its structural activity and was not reproduced by its DNA analog deoxy-inosine (ssdIA), while also favoring structural variations (Fig. 2). This inhibition of immunostimulatory activity by the DNA analog of inosine is similar to that seen with deoxy-uridine residues, which repress sensing of ssRNAs when replacing uridine residues (37).

TLR7/8 can be activated by ssRNA and dsRNA, although the immunostimulatory role of dsRNA is greater when the affinity for the dsRNA duplex is weaker, particularly for TLR8 (18,19). In the context of viral infection, we therefore hypothesized that ADAR-1L-mediated A-to-I editing of structured RNAs could facilitate TLR7/8 sensing by destabilizing dsRNA structures. However, immunostimulatory analyses of individual ssRNAs mimicking a known structured hyperedited region of influenza A virus indicated that A-to-I editing did not enhance TLR7/8 sensing when present in 100% of the molecules (Fig. 6). In fact, an ~50% decrease in human TNF-α was even visible with one of the sequences (S2i) and when the sequences were pooled, indicating an inhibitory effect of A-to-I editing on TLR8 sensing. While counterintuitive in light of our other results with ssRNAs where inosine incorporation was not restricted to adenosine residues (Fig. 1, 2, and 3), we propose that this relates to the loss of TLR8-specific AU-rich motifs (changed to IU motifs) (17). In line with this concept, S2i ssRNA lost three AU motifs following A-to-I editing and displayed a marked decrease in TNF-α, while IFN-α levels were unaffected when transfected in human PBMCs. Further involving TLR8 in this event, pools of inosine-modified ssRNAs did not promote such a decrease in TNF-α production in mouse macrophages, in which Tlr8 does not contribute to ssRNA sensing (13). It is also possible that changes in secondary structure less favorable to the detection of these ssRNAs are also at play.

Nonetheless, under the rationale that A-to-I editing affected only small proportions of viral RNAs, we postulated that the observed structural effects of inosine on ssIA and B-406-AS-i ssRNA could increase the formation of complex intermolecular structures in A-to-I edited RNA, even if present in a small proportion of sequences. Accordingly, we demonstrate here that physiological levels (between 1 and 12.5%) of inosine-modified ssRNA molecules can potentiate RNA sensing and result in increased TNF-α production by human and mouse macrophages. We propose that this potentiation is mostly TLR8 dependent in human PBMCs, as revealed by the preferential increase in TNF-α production. As such, A-to-I editing exhibits a dual activity, which can both potentiate and antagonize TLR8 sensing, the latter diminishing with a biologically relevant low concentration of inosine-modified RNAs. Noteworthy, we have previously shown that human TLR7 was necessary for ssRNA sensing in human monocytes (22), and it is thus most likely that TLR7 is also at play in the macrophage sensing of inosine-modified RNA. We directly establish a role for mouse Tlr7 in the effect of inosine-modified ssRNA molecules, through the use of Tlr7−/− macrophages (Fig. 6). This role for Tlr7 in the increased detection of A-to-I edited viral RNA is consistent with recent reports demonstrating a critical role for mouse Tlr7 in the immune response to lymphocytic choriomeningitis virus (LCMV) (15,16), which is subject to ADAR-1L hyperediting during replication (10).

Finally, in support of a direct role for A-to-I editing in the sensing of viral RNA by TLR7/8, we show a correlation between the proportion of hyperedited influenza virus RNA and the immunostimulatory activity of this viral RNA in human PBMCs. As with our observations on pools of inosine-modified RNAs, TNF-α was predominantly affected by the overall proportion of hyperedited RNA, suggesting preferential modulation of TLR8 activity. Critically, we also demonstrate that phagocytosis of total RNA from influenza virus-infected cells resulted in TNF-α production by human and mouse macrophages, independently of 5′-triphosphate residues and in an Adar−1-dependent manner. Although the direct antiviral activity of 5′-triphosphate-dependent IFN-α production was clearly predominant in these experiments, these results confirm a contributing role for human TLR8 and mouse Tlr7 to the sensing of RNA from infected epithelial cells. Because modified cellular RNA is essentially nonimmunostimulatory, it remains to be determined whether inosine residues directly compete with inhibitory moieties such as 2′-O-methyl bases, to result in TLR7/8 sensing. Altogether, our results support a role for TLR7/8 in the production of TNF-α by macrophages in response to phagocytosed infected epithelial cells. In addition to its direct proinflammatory activity, TNF-α was previously shown to enhance influenza virus-induced chemokine expression by epithelial
cells (38). This suggests a possible feedback loop between epithelial cells and macrophages, increasing immune cell recruitment to the infected locus.

Collectively, our data establish a novel role for TLR7/8 in the detection of A-to-I edited viral RNA. We propose that Adar-1-mediated inosine incorporation into viral RNA acts to facilitate recognition of nonself RNA by TLR7/8, allowing infected cells to be identified when cleared by phagocytes, such as macrophages. It is unlikely that inosine-modified viral RNA contributes directly to the antiviral response against infected epithelial cells, as they lack TLR7/8 (13). We speculate that A-to-I editing of structured viral RNA helps to counterbalance the repressive effect of self-RNA from phagocytosed infected cells, thus helping to distinguish between self and nonself RNA, together with other modifications such as 5′–triphosphate (1). Along with reports on TLR3 sensing (11, 12), the implications of our work may be far-reaching, as our results suggest a novel paradigm whereby A-to-I editing of viral RNA acts to facilitate detection of nonself RNA.

ACKNOWLEDGMENTS
This work was supported by funding from the Australian National Health and Medical Research Council (1022144 to M.P.G. and 1006590 to B.R.G.W.), a Monash University Faculty of Medicine, Nursing and Health Sciences Grant (2012), and the Victorian Government’s Operational Infrastructure Support Program.

We are grateful to Vivien Vasic, Trevor Wilson, Ross Chapman, and Jodee Gould (Monash Health Translation Precinct Medical Genomics Facility—Australian Cancer Research Foundation Centre for Cancer Genomic Medicine) for their help with Ion Torrent sequencing, Scott Rose (Integrated DNA Technologies Inc.) for his help in the production of the RNA oligonucleotides, and Kun Xiao (La Trobe University) for his help with mouse work. Mark A. Behlke and Ashley M. Jacobi are employed by Integrated DNA Technologies Inc. (IDT), which offers oligonucleotides for sale similar to some of the compounds described in the manuscript. IDT, however, is not a publicly traded company, and these authors do not own any shares or hold equity in IDT.

REFERENCES


